Skip to main content

Table 4 Postoperative outcomes

From: Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

  Control group, mean ± SD (n = 15) Prehabilitation group, mean ± SD (n = 14) p-value
Hospital stay (days) 7.8 ± 6.8 7.4 ± 5.0 0.700
ICU stay (days) 1.2 ± 0.6 1.2 ± 0.9 0.959
Time to start CT of surgery day (days) 39.9 ± 14.3 37.4 ± 9.2 0.602
Pain VAS day 1 1.6 ± 1.7 1.7 ± 1.7 0.856
Pain VAS day 2 1.2 ± 1.0 1.4 ± 1.4 0.736
Diet restart (days) 1.7 ± 0.8 1.3 ± 0.6 0.169
Deambulation restart (days) 3.1 ± 1.2 2.9 ± 1.4 0.678
Postoperative complications, n (%)
 Non reported 6 (40.0) 4 (28.6) 0.518
 Reported 9 (60.0) 10 (71.4)
Postoperative complications
 Paralytic ileus 2 (13.3) 1 (7.1) 0.584
 Surgical site infection (superficial and deep) 6 (40.0) 5 (35.7) 0.812
 Surgical site infection (organ and space) 2 (13.3) 0 (0) 0.157
 Anastomosis breakdown 2 (13.3) 0 (0) 0.157
 Cardiovascular 1 (6.7) 0 (0) 0.326
 Respiratory 3 (20.0) 1 (7.1) 0.316
 Neurological 0 (0) 2 (14.3) 0.129
 Urinary tract infection 4 (26.7) 1 (7.1) 0.164
 Multiorgan failure 1 (6.7) 0 (0) 0.326
Surgical reintervention 1 (6.7) 1 (7.1) 0.960
Clavien-Dindo complications
 I 4 (26.7) 4 (28.6) 0.486
 II 10 (66.7) 8 (57.1)
 III 0 (0) 1 (7.1)
 IV 0 (0) 1 (7.1)
 V 1 (6.7) 0 (0)
Readmissions 2 (13.3) 3 (21.4) 0.564
  1. CT chemotherapy, ICU intensive care unit, SD standard deviation, VAS visual analog scale